China to India Pharmaceutical Import

The pharmaceutical trade corridor between China and India has experienced significant growth over the past decade. In 2022, India's pharmaceutical imports from China were valued at approximately $767.5 million USD, encompassing 4,376 shipments from 416 Chinese suppliers to 231 Indian buyers. This surge reflects China's expanding role as a key supplier of finished pharmaceutical formulations to India. The trade has been characterized by a diverse range of products, with sodium, heparin, and potassium leading the import categories. Notably, the average shipment value stands at $175,000 USD, indicating a mix of bulk and specialized pharmaceutical products.

China has become a pivotal source of pharmaceutical imports for India, supplying a wide array of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The dominance of sodium, heparin, and potassium in the import list underscores China's strength in producing essential and high-demand pharmaceutical ingredients. This trend highlights China's capacity to meet India's growing pharmaceutical needs, particularly in critical therapeutic areas.

Between 2024 and 2026, the Central Drugs Standard Control Organisation (CDSCO) has implemented several policy changes to streamline the import process and enhance the quality of imported pharmaceuticals. These initiatives include revising registration procedures, updating Good Manufacturing Practice (GMP) standards, and introducing stricter quality control measures. Additionally, trade agreements and regulatory harmonization efforts have been pursued to facilitate smoother trade relations and ensure the safety and efficacy of imported pharmaceutical products.

For Chinese pharmaceutical companies aiming to export finished formulations to India, obtaining CDSCO registration is mandatory. The process involves several key steps:

1. Application Submission: Companies must submit an online application through the CDSCO portal, providing detailed information about the product and manufacturing site.

2. Documentary Requirements: Essential documents include a valid manufacturing license, Certificate of Pharmaceutical Product (CPP), Free Sale Certificate, and a site master file detailing manufacturing processes.

3. Clinical Trial Data: Depending on the product, clinical trial data may be required. However, CDSCO may grant waivers for certain products based on existing approvals in other jurisdictions.

4. Review and Approval: CDSCO evaluates the application to ensure compliance with Indian standards. This may involve inspections and consultations with subject-matter experts.

The entire registration process can take several months, depending on the complexity of the product and the completeness of the application.

India mandates that all imported pharmaceutical products adhere to stringent GMP standards to ensure quality and safety. Chinese manufacturing sites must comply with these standards, which are aligned with international guidelines. CDSCO conducts inspections to verify compliance, and products must be WHO prequalified or meet equivalent standards. Non-compliance can result in rejection of the import application and potential bans on future shipments.

Importing pharmaceutical products into India requires comprehensive documentation:

1. Import License (Form 10): Issued by CDSCO, this license authorizes the import of specific pharmaceutical products.

2. Registration Certificate: Confirms that the product has been approved for sale in India.

3. No Objection Certificate (NOC): Required for certain products, indicating no objection from the manufacturer or other regulatory bodies.

4. Test License: Allows for testing of the imported product to ensure it meets Indian standards.

5. Customs Procedures: Compliance with Indian customs regulations is essential, including proper labeling, packaging, and payment of applicable duties and taxes.

India's pharmaceutical imports from China are predominantly composed of essential therapeutic products. Sodium, heparin, and potassium lead the import categories, reflecting China's capacity to supply critical raw materials and finished formulations. The inclusion of insulin, vaccines, and antibiotics like piperacillin and amoxicillin indicates China's role in providing a diverse range of pharmaceutical products to meet India's healthcare needs.

China's pharmaceutical exports to India include innovative and specialty products not widely manufactured domestically. The presence of biologics, such as insulin and vaccines, and advanced therapies like semaglutide, highlights China's growing capabilities in producing complex pharmaceutical formulations. These products are crucial for treating a variety of diseases and conditions prevalent in India.

India's reliance on pharmaceutical imports from China is driven by several factors:

1. Patent Protection: Imported drugs may be under patent protection in India, limiting domestic production.

2. Technology Gaps: China's advanced manufacturing technologies enable the production of complex formulations not yet developed in India.

3. Quality Requirements: Imported products often meet international quality standards, ensuring efficacy and safety.

4. Disease Burden: The prevalence of certain diseases in India necessitates the import of specific pharmaceutical products to meet treatment demands.

India's import tariff structure for pharmaceutical formulations includes:

1. Most Favored Nation (MFN) Tariff Rates: Standard rates applied to imports from all WTO member countries.

2. Basic Customs Duty: A percentage of the product's value, varying based on the product category.

3. Integrated Goods and Services Tax (IGST): Applied to imported goods, including pharmaceuticals, at rates specified by the government.

4. Health Cess: An additional levy on imported medical devices and drugs to fund health initiatives.

These tariffs are subject to change based on government policies and international trade agreements.

India and China are not part of a Free Trade Agreement (FTA). However, both countries are members of the Regional Comprehensive Economic Partnership (RCEP), which aims to reduce trade barriers among member nations. While RCEP may offer some preferential duty rates, specific benefits for pharmaceutical imports depend on the finalization and implementation of the agreement's provisions.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, allows for the granting of compulsory licenses under certain conditions, facilitating the production of generic versions of patented drugs. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including imported drugs, to ensure affordability. These policies aim to balance the interests of patent holders and public health needs.

Pharmaceutical shipments from China to India primarily utilize sea and air routes. Major sea routes involve ports such as Shanghai and Shenzhen in China, with transit times ranging from 7 to 14 days, depending on the specific ports and shipping conditions. Air shipments, though more expensive, offer faster delivery times, typically within 3 to 5 days. The reliability of these routes is generally high, but subject to factors like weather conditions and geopolitical events.

Key Chinese export ports handling pharmaceutical shipments include Shanghai, Shenzhen, and Guangzhou. In India, major import ports include Mumbai, Chennai, and Kolkata. These ports are equipped with facilities to handle pharmaceutical products, ensuring compliance with international shipping standards and regulations.

Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes verification of documentation, payment of applicable duties, and inspection for compliance with Indian regulations. The CDSCO conducts testing to ensure product quality and safety. For temperature-sensitive products, adherence to cold chain logistics is critical, with compliance to Good Distribution Practices (GDP) ensuring product integrity throughout the supply chain.

Despite being a major pharmaceutical manufacturer, India imports a significant portion of its pharmaceutical products from China. This dependency is due to factors such as the need for specific patented drugs, advanced biologics, and specialized formulations not yet produced domestically. Additionally, China's competitive pricing and established manufacturing capabilities make it a preferred source for many pharmaceutical products.

Several Chinese pharmaceutical companies have established a presence in India, either through direct exports, partnerships, or contract manufacturing agreements. These companies employ strategies such as joint ventures with Indian firms, setting up local manufacturing facilities, and engaging in research and development collaborations to cater to the Indian market.

India's "Atmanirbhar Bharat" initiative and the Production Linked Incentive (PLI) scheme aim to boost domestic manufacturing and reduce reliance on imports. While these efforts are expected